Alnylam Pharmaceuticals Inc. reported total revenues of $1,249.0 million for the third quarter ended September 30, 2025, representing a 149% increase from $500.9 million in the same period in 2024. The company reported GAAP income from operations of $368.0 million, compared to a GAAP loss from operations of $76.9 million in the third quarter of 2024. Non-GAAP income from operations was $476.2 million, compared to a non-GAAP loss from operations of $31.1 million in the prior-year period. GAAP net income was $251.1 million, compared to a net loss of $111.6 million in the third quarter of 2024. Alnylam raised its 2025 total net product revenues guidance to a range of $2.95 billion to $3.05 billion, citing growth in its TTR franchise and the ongoing launch of AMVUTTRA for ATTR-CM. Other business developments in the period included the initiation of new Phase 3 trials for zilebesiran in hypertension and nucresiran in hATTR-PN, plans to initiate a Phase 2 trial of mivelsiran in Alzheimer's disease in the fourth quarter of 2025, and the appointment of Bryan Supran as Executive Vice President, Chief Legal Officer and Secretary. The company issued $661 million in convertible senior notes due 2028 and entered into a $500 million revolving credit facility. Alnylam also received a subpoena from the U.S. Attorney's Office for the District of Massachusetts regarding government price reporting for several products.